CJC-1295 with DAC Dosage Guide: Protocols, Calculator & Safety

Entry protocol — first CJC-1295 with DAC cycle

Goal: Establish tolerance, detect side effects, calibrate IGF-1 response.

Prerequisites

1. Baseline IGF-1, IGFBP-3, fasting glucose, HbA1c
2. Comprehensive cancer screening up to date per age
3. No active or recent malignancy
4. No diabetic retinopathy
5. Vendor COA: ≥98% purity, correct sequence, DAC moiety verified, endotoxin <1 EU/mg
6. Bacteriostatic water 0.9% benzyl alcohol
7. Insulin syringes 29-31G × 1/2"

Reconstitution (2 mg DAC vial, 2 mL BAC)

• Concentration: 1 mg/mL = 1000 mcg/mL
• For 1 mg weekly dose: draw 0.1 mL = 100 units (or 1 mL on insulin syringe)
• Wait — 100 units on a U-100 insulin syringe = 1.0 mL. Correct draw is 100 units = 1 mL = 1000 mcg

Most practitioners use 1 mg per week starting dose, escalating to 2 mg if needed.

Cycle 1 — 12 weeks

Week 1-4: 1 mg DAC weekly, same day each week

• Injection evening, pre-bed (not critical due to sustained release)
• SC lower abdomen, thigh, or upper arm; rotate
• No other GH-axis agents

Track weekly:

• Injection-site reaction
• Flushing intensity
• Sleep quality
• Fluid retention (ring tightness, sock marks)
• Hand numbness/tingling

Week 4 labs:

• IGF-1 (check elevation; target upper-normal for age)
• Fasting glucose
• CBC

Week 5-12: continue 1 mg weekly

• If IGF-1 in range and tolerated → continue
• If IGF-1 too high or side effects → reduce to 0.5 mg weekly
• If IGF-1 minimal rise → consider 2 mg (rare; usually indicates sourcing issue)

Week 12 labs:

• Full panel: IGF-1, IGFBP-3, fasting glucose, HbA1c, CMP, CBC
• Symptom assessment

Decision point at 12 weeks:

• IGF-1 upper-normal + benefit + no side effects → continue with 4-week break
• Persistent side effects → stop or switch to MOD-GRF 1-29 + ipamorelin (more tolerable)
• No benefit → stop; DAC may not be the right tool

Red flags — stop

• Glucose >105 mg/dL fasting or HbA1c rising
• Persistent carpal tunnel symptoms
• New joint pain or swelling
• Any suspicion of malignancy
• Unexplained fatigue or new symptoms

Honest note

Most experienced peptide clinicians recommend starting with MOD-GRF 1-29 + ipamorelin (non-DAC) before ever trying DAC. The pulsatile profile is safer, side effects are more manageable, and if it doesn't meet goals, DAC can be added later. Starting with DAC first is historically the wrong direction on the pharmacologic sophistication ladder.

Intermediate protocol — continuing beyond initial cycle

Assumes 12-week introductory cycle complete, no adverse events, clear benefit, IGF-1 appropriately elevated.

Standard dosing

• 1-2 mg DAC SC weekly, same day each week
• Same SC site rotation
• Target IGF-1: 70-80th percentile for age (not higher)

Dose adjustment

• IGF-1 > age-specific upper limit → reduce 25% (e.g., 2 → 1.5 mg weekly)
• IGF-1 at high-normal + significant benefit → maintain
• IGF-1 mid-normal + no benefit → increase to 2 mg (if not already); if still no response at 2 mg, DAC is not the right tool

Cycling

• 12 weeks on, 4 weeks off (quarterly)
• Or 6 months on, 1 month off (biannual)
• Annual 4-6 week break minimum

Stacking

• BPC-157 250 mcg BID for recovery and gut health (no conflict)
• TB-500 2 mg weekly for connective tissue recovery (no conflict)
• Creatine 5 g/day
• Vitamin D3 + K2 + magnesium standard
• Consider adding ipamorelin 200 mcg pre-bed if additional pulsatile GH desired (controversial)
• NAD+ precursors for broader longevity stack
• Avoid simultaneous MOD-GRF 1-29 (redundant)

Monitoring cadence

• IGF-1 quarterly for first year, then biannually
• Fasting glucose and HbA1c quarterly
• CBC, CMP biannually
• Annual cancer screening per USPSTF (no different from non-users)
• Body composition (DEXA) every 6-12 months
• Ophthalmologic evaluation annually if type 2 diabetes or family history

Managing side effects

• Edema: reduce dose 25%; monitor sodium intake
• Carpal tunnel: reduce dose 25%; nighttime wrist splints
• Joint stiffness: reduce dose 25%; add EPA/DHA 2 g/day
• Glucose rising: reduce dose, increase aerobic exercise, reassess diet

Pharmacokinetic considerations

• If switching off DAC: expect 3-4 weeks washout
• Cannot be "paused" for 1 week and resumed — the sustained release prevents fine-grained dose timing
• If overt side effects develop, it takes days to weeks for full resolution after discontinuation

When to switch to non-DAC form

• If pulsatile physiology is desired (most clinicians recommend this)
• If persistent side effects from sustained elevation
• If tighter IGF-1 control needed (DAC gives plateau, non-DAC gives pulses that are easier to dial in)
• If stacking with daily ipamorelin for optimal synergy

Stop immediately if

• Active cancer diagnosis
• New diabetic retinopathy
• Significant cardiac symptoms
• Pregnancy desire → wait 3 months before conception attempts
• Unexplained weight gain >3 kg in 30 days (fluid or other)

Advanced protocol — longitudinal DAC use

This tier assumes successful 12+ month history with DAC, well-characterized personal response, and no safety concerns on surveillance.

Most advanced users eventually transition to non-DAC

This is worth stating plainly. The overwhelming majority of experienced peptide clinicians prefer MOD-GRF 1-29 + ipamorelin (non-DAC) for long-term use because:

• Pulsatile physiology is preserved
• Somatotroph sensitivity maintained
• Side effects are more manageable
• Dose adjustment is granular
• Timing of GH peaks aligns with training or sleep

DAC's advantage — weekly dosing convenience — often fades in importance after users become proficient with daily injections.

If continuing DAC long-term

Dose:

• 1-2 mg weekly (most users)
• Do not escalate above 2 mg weekly (diminishing returns, increasing side effects)
• Target IGF-1: 70-80th percentile age-specific, stable

Cycling:

• Quarterly breaks (12 on / 4 off) essential
• Annual month-long breaks minimum
• Long-term continuous DAC use without any breaks: not recommended

Comprehensive monitoring (quarterly):

• IGF-1, IGFBP-3
• Fasting glucose, fasting insulin, HbA1c, HOMA-IR
• Lipid panel
• hs-CRP
• CBC, CMP

Annual (above baseline):

• Echocardiogram after 3 years continuous use (conservative, no definitive evidence)
• DEXA body composition
• Age-appropriate cancer screening (non-negotiable)
• Carotid intimal-media thickness (if atherosclerosis risk)

Stacks for advanced users

• DAC 1-2 mg/week
• BPC-157 250 mcg BID
• TB-500 2 mg weekly
• NAD+ / NMN 500 mg daily
• Testosterone replacement (if indicated, clinician-supervised)
• Vitamin D + K2 + magnesium + omega-3
• Creatine
• Annual hiatus from all growth-axis peptides for 4-6 weeks

What advanced users should NOT do

• Exceed 2 mg weekly DAC dose
• Add MOD-GRF 1-29 simultaneously
• Chase higher IGF-1 ("more is better" mentality)
• Stack with IGF-1 LR3 or MGF
• Continue through any malignancy workup
• Ignore rising fasting glucose

When to stop

• Any cancer diagnosis
• New diabetic retinopathy
• Persistent fasting glucose >105 or HbA1c >5.7 despite dose reduction
• Acromegaly-like features (rare at therapeutic dosing)
• Pregnancy planning (stop 3 months before)
• Loss of benefit despite appropriate IGF-1 and adherence

Transitioning off

• Expect 3-4 weeks washout
• IGF-1 returns to baseline over 4-6 weeks
• GH axis returns to full pulsatile function within 1-2 months
• No specific taper required; simply stop

Realistic assessment

DAC is a legitimate tool with clear pharmacokinetic advantages (convenience, sustained IGF-1). Its disadvantages (non-pulsatile physiology, limited dose granularity, higher side-effect rate) make it a less-preferred option in most modern protocols. Long-term safety at the 3-5+ year horizon is under-characterized. Users who choose DAC should do so with eyes open to both its efficiency and its limitations.